The contribution of vaccination to global health: Past, present and future

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 369, Issue 1645, 2014, Pages

  Greenwood, Brian ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Global health; Vaccination; Vaccine development

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE SYSTEM; IMMUNIZATION; MEASLES; PNEUMONIA; SMALLPOX; VACCINATION; VACCINE;

EID: 84900346623     PISSN: 09628436     EISSN: 14712970     Source Type: Journal    
DOI: 10.1098/rstb.2013.0433     Document Type: Review

References (44)

1. Glynn I, Glynn J. 2004 The life and death of smallpox. Cambridge, UK: Cambridge University Press.
2. Allen A. 2007 Vaccine-the controversial story of medicine's greatest lifesaver. New York, NY: W.W. Norton & Co.
3. Weber TP. 2010 Alfred Russel Wallace and the antivaccination movement in Victorian England. Emerg. Infect. Dis. 16, 664-668. (doi:10.3201/ eid1604.090434)
4. Henderson DA. 2009 Smallpox-the death of a disease. Amherst, NY: Prometheus Books.
5. Roeder P, Mariner J, Kock R. 2013 Rinderpest: the veterinary perspective on eradication. Phil. Trans. R. Soc. B 368, 20120139. (doi:10.1098/ rstb.2012.0139)
6. Youde J. 2013 Cattle scourge no more. The eradication of rinderpest and its lessons for global health campaigns. Politics Life Sci. 32, 43-57. (doi:10.2990/32_1_43)
7. Geison GL. 1995 The private science of Louis Pasteur. Princeton, NJ: Princeton University Press.
8. Wu X, Smith TG, Rupprecht CE. 2011 From brain passage to cell adaptation: the road of human rabies vaccine development. Expert Rev. Vac. 10, 1597-1608. (doi:10.1586/erv.11.140)
9. Wilson JR. 1963 Margin of safety. The story of the poliomyelitis vaccine. London, UK: Collins.
10. Nuttall JJ, Eley BS. 2011 BCG vaccination in HIVinfected children. Tuberc. Res. Treat. 2011, 712736. (doi:10.1155/2011/712736)
11. Lu YJ et al. 2010 GMP-grade pneumococcal wholecell vaccine injected subcutaneously protects mice from nasphayngeal colonization and fatal aspiration-sepsis. Vaccine 28, 7468-7475. (doi:10. 1016/j.vaccine.2010.09.031)
12. Pombo DJ et al. 2002 Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet 360, 610-617. (doi:10.1016/S0140-6736(02)09784-2)
13. Seder RA et al. 2013 Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 341, 1359-1365. (doi:10.1126/science.1241800)
14. Wakefield AJ et al. 1998 Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 351, 637-641. (doi:10.1016/S0140-6736(97)11096-0)
15. World Health Organisation. 2013 Global routine vaccination coverage 2012. Wkly Epidemiol. Rec. 88, 482-485.
16. Van Panhuis WG et al. 2013 Contagious diseases in the United States from 1888 to the present. N. Engl. J. Med. 369, 2152-2158. (doi:10.1056/ NEJMms1215400)
17. Benn CS, Netea MG, Selin LK, Aaby P. 2013 A small jab-a big effect: nonspecific immunomodulation by vaccines. Trends Immunol. 34, 431-439. (doi:10. 1016/j.it.2013.04.004)
18. Aaby P et al. 2011 Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period? J. Infect. Dis 204, 245-252. (doi:10.1093/infdis/jir240)
19. Kleinnijenhuis J et al. 2012 Bacillle Calmette-Guérin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc. Natl Acad. Sci. USA 109, 17 537-17 542. (doi:10.1073/pnas.1202870109)
20. Arora NK, Lal AA, Hombach JM, Santos JI, Bhutta ZA, Sow SO, Greenwood B. 2013 The need for targeted implementation research to improve coverage of basic vaccines and introduction of new vaccines. Vaccine 31S, B129-B136. (doi:10.1016/j. vaccine.2013.01.058)
21. Glass RI, Parashar UD. 2014 Rotavirus vaccines-balancing intussusception risks and health benefits. N. Engl. J. Med. 370 568-570. (doi:10.1056/ NEJMe1315836)
22. Editorial. 2013 Polio eradication: where are we now? Lancet 382, 1381.
23. World Health Organisation. 2013 Polio Eradication and Endgame Strategic Plan 2013-2018. Geneva, Switzerland: World Health Organisation.
24. United Nations Children's Fund. 2013 Committing to child survival: a promise renewed. New York, NY: UNICEF publications.
25. Klugman KP et al. 2008 Meta-analysis of the efficacy of conjugate vaccines against invasive pneumococcal diseases. In Pneumococcal vaccines: the impact of conjugate vaccine (eds GR Siber, KP Klugman, PH Mäkela), pp. 317-326. Washington, DC: ASM Press.
26. Glass RI, Parashar U, Patel M, Gentsch J, Jiang B. 2013 Rotavirus vaccines: Successes and challenges. J. Infect. 68, S9-S18. (doi:10.1016/j.jinf.2013. 09.010)
27. Levine OS, Bloom DE, Cherian T, de Quadros C, Sow S, Wecker J, Duclos P, Greenwood B. 2011 The future of immunisation policy, implementation, and financing. Lancet 378, 439-448. (doi:10.1016/ S0140-6736(11)60406-6)
28. Crosignani P et al. 2013 Towards the eradication of HPV infection through universal specific vaccination. BMC Public Health 13, 642. (doi:10.1186/1471-2458-13-642)
29. Daugla D et al. 2013 Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community trial. Lancet 383, 40-47. (doi:10.1016/S0140-6736(13)61612-8)
30. Sabchareon A et al. 2012 Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 380, 1559-1567. (doi:10.1016/S0140-6736(12)61428-7)
31. RTS S, Clinical Trials Partnership. 2011 First results of phase 3 trial of RTS, S/ASO1 malaria vaccine in African children. N. Engl. J. Med. 365, 1863-1875. (doi:10.1056/NEJMoa1102287)
32. RTS S, Clinical Trials Partnership. 2012 A phase 3 trial of RTS, S/AS01 malaria vaccine in infants. N. Engl. J. Med. 367, 2284-2295. (doi:10.1056/ NEJMoa1208394)
33. Rerks-Ngarm S et al. 2009 Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361, 2209-2220. (doi:10.1056/ NEJMoa0908492)
34. Tameris MD et al. 2013 Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 381, 1021-1028. (doi:10.1016/S0140-6736(13)60177-4)
35. Rappuoli R, Aderem A. 2011 A 2020 vision for vaccines against HIV, tuberculosis and malaria. Nature 473, 463-469. (doi:10.1038/nature10124)
36. Koff WC, Burton D, Johnson PR, Walker BD, King CR, Nabel GJ, Ahmed R, Bhan MK, Plotkin SA. 2013 Accelerating next-generation vaccine development for global disease prevention. Science 340, 1232910. (doi:10.1126/science.1232910)
37. Nabel GJ. 2013 Designing tomorrow's vaccines. N. Engl. J. Med. 368, 551-560. (doi:10.1056/ NEJMra1204186)
38. Pearson FE et al. 2013 Dry-coated live viral vector vaccines delivered by nanopatch microprojections retain long-term thermostability and induce transgene-specific T cell responses in mice. PLoS ONE 8, e67888. (doi:10.1371/journal.pone.0067888)
39. Edens C, Collins ML, Ayers J, Rota PA, Prausnitz MR. 2013 Measles vaccination using a microneedle patch. Vaccine 31, 3403-3409. (doi:10.1016/j. vaccine.2012.09.062)
40. Moxon R, Snape MD. 2013 The price of prevention: what now for immunisation against meningococcus B? Lancet 382, 369-370. (doi:10.1016/S0140-6736(13) 61572-X)
41. Liu MA. 2011 Cancer vaccines. Phil. Trans. R. Soc. B 366, 2823-2826. (doi:10.1098/rstb.2011.0101)
42. Bachmann MF, Jennings GT. 2011 Therapeutic vaccines for chronic diseases: successes and technical challenges. Phil. Trans. R. Soc. B 366, 2815-2822. (doi:10.1098/rstb.2011.0103)
43. Maurer P, Bachmann MF. 2007 Vaccination against nicotine: an emerging therapy for tobacco dependence. Expert. Opin. Investig. Drugs 16, 1775-1783. (doi:10.1517/13543784.16.11.1775)
44. Winblad B et al. 2012 Safety, tolerability, and antibody response of active Ab immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, firstin-human study. Lancet Neurol. 11, 597-604. (doi:10.1016/S1474-4422(12)70140-0)